ISR AB

ISR Immune System Regulation Holding AB is an innovation driven Research Company within the area of immunotherapy, based at the Karolinska Hospital (SE).

[ISR AB @ISR_Innovation]

Presentation by Nigel Goodman (Head of Clinical Operations at ISR) from last weeks symposium in Lund:

https://t.co/72dXhRKSI7

[ISR AB @ISR_Innovation]

@BScMechatronics I received a sms in regards of this as well, and of course it should be October 25th. As one can’t edit the tweets, I’ve now published a new with the correct date. Sorry for any inconvenience.

[ISR AB @ISR_Innovation]

Next week, on October 23rd, our partner Iconovo arranges this symposia, where- among others - our CEO Ola Winqvist will present:

https://t.co/ASmTdlUOrx

[ISR AB @ISR_Innovation]

Unfortunately we published the wrong date for this event. Corrected below.

Next week, on October 25th, our partner Iconovo arranges this symposia, where- among others - our CEO Ola Winqvist will present:

https://t.co/ASmTdlUOrx

[ISR AB @ISR_Innovation]

Redeye’s CEO interview with Ola Winqvist:

https://t.co/BxdzUGcIIq

[ISR AB @ISR_Innovation]

Link to yesterdays conference call in regards of the financial report for the 1st half of 2022
https://t.co/oL4Sb9sJdJ

[ISR AB @ISR_Innovation]

Link to our Chief of Clinical Operations, Nigel Goodmans presentation at yesterdays Redeye event:
https://t.co/m8NLTG6QwC

[ISR AB @ISR_Innovation]

Report for the 1st half of 2022:

https://t.co/OwRkV0y5I0

[ISR AB @ISR_Innovation]

One important step in the development of an effective treatment within HIV, by the closing of inclusion of new patients. Next step is the closing of the trial, which will be in late 2022.

https://t.co/FdnS1Lyu5F

[ISR AB @ISR_Innovation]

Half Year Report for 2022 is postponed due to a heavy workload from parallel activities. New date is set to August 31

https://t.co/kVh1RqlE8i

[ISR AB @ISR_Innovation]

With the approval from BMRC NREC, we are taking significant steps, and keeping pace in order to have ”first-patient-in” in Q4 2022, for our dry-powder nasally inhaled SARS-CoV-2 vaccine - ISR 052.

https://t.co/Ungo5paI8z

[ISR AB @ISR_Innovation]

One step further in the process towards an intranasally inhaled, dry-powder solution for SARS-CoV-2 vaccine to humanity

https://t.co/hAazLGAC5u

[ISR AB @ISR_Innovation]

ISR-052 provides long-term protection against SARS-CoV-2
https://t.co/YUV7aVjYE5

[ISR AB @ISR_Innovation]

Redeye Growth Day June 2nd, ISR presentation with our CEO Ola Winqvist for preview, which will be followed by live a interview/discussion led by our Redeye analyst, Ethel Luvall, external sector specialist and our CEO Ola.

https://t.co/V3s6185zx3

[ISR AB @ISR_Innovation]

Today, we’ve published the Annual Report for 2021 with a new and more illustrative and attractive layout. We hope you’ll like it!

https://t.co/hFShpuxTU3

[ISR AB @ISR_Innovation]

Press Release from our partner Iconovo today:

https://t.co/lDpdwQLkjj

[ISR AB @ISR_Innovation]

ISR’s taking important steps in scaling up production for future needs to the ISR052 - or dry-powder intranasal Covid-19 vaccine:

https://t.co/Jm3yhjh8or

[ISR AB @ISR_Innovation]

After participating the https://t.co/HxiywvWBPj in London, we’ve attended the Redeye AW in Malmoe this week. A lot is happening now, in preparing for the clinical phase for ISR52 and the development of other products in our pipeline.

Wishing you all a fantastic weekend❤️🥂

[ISR AB @ISR_Innovation]

From yesterdays presentation at Redeye AW in Malmö.

https://t.co/NVA4CLinR7

[ISR AB @ISR_Innovation]

Last week, Redeye initiated analyst coverage for ISR.

https://t.co/MrbUKooTjc